Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase

British Journal of Cancer

Volumn 76, Issue 4, 1997, Pages 438-444

  Butler, S A ^a   Wood, P J ^a   Cole, S ^a   Williams, C ^a   Adams, G E ^a   Stratford, I J ^a,b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Bioreductive drug; Experimental murine tumour; Hypoxia; Nitric oxide synthase; RB6145

Indexed keywords

1 (2 BROMOETHYLAMINO) 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR VOLUME;

EID: 0030757021     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.407     Document Type: Article

References (42)

1. Andrade SP, Hart IR, and Piper PJ (1942) Inhibitors of nitric oxide sythase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol 107: 1092-1097
2. Austin PE, McCulloch EA and Till JE (1971) Characterization of the factor in L-cell conditioned medium capable of stimulating colony formation by mouse marrow cells in culture. J Cell Physiol 77: 121-133
3. Binger M and Workman P (1991) Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromeothylamino prodrug (RB6145) of the mixed-function hypoxic cell sensitizer/cytotoxin a-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU1069). Cancer Chemother Pharmacol 29: 37-47
4. Bremner JCM (1993) Assessing the bioreductive effectiveness of the nitromidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation. Cancer Metastasis Rev 12: 177-193
5. Bremner JCM, Stratford IJ, Bowler J and Adams GE (1990) Bioreductive drugs and the selective induction of tumour hypoxia. Br J Cancer 61: 717-721
6. Brown JM (1977) Cytotoxic effects of the hypoxic cell radiosensitizer Ro 7-0582 to tumor cells in vivo. Radiat Res 72: 469-486
7. Brown JM, Yu NY, Cory MJ, Bicknell RB and Taylor DL (1978) In vivo evaluation of the radiosensitizing and cytotoxic properties of newly synthesized electronaffinic drugs. Br J Cancer 37 (suppl. 3): 206-211
8. Castellino SM, Friedman HS, Elion GB, Ong ET, Marcelli SL, Page R, Bigner DD and Dewhirst MW (1995) Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma. Br J Cancer 71: 1181-1187
9. Chaplin DJ (1986) Potentiation of RSU1069 tumour cytoxicity by 5-hydroxytryptamine (5-Ht). Br J Cancer 54: 727-731
10. Chaplin DJ (1989) Hydralazine induced tumour hypoxia: a potential target for cancer chemotherapy. J Natl Cancer Inst 81: 618-622
11. Chaplin DJ and Acker B (1987) Potentiation of RSU1069 tumour cytoxicity by hydralazine: a new approach to selective therapy. Int J Radiol Oncol Biol Phys 13: 579-585
12. Chaplin DJ and Trotter MJ (1991) Chemical modifiers of tumour blood flow. In Tomour Blood Supply and Metabolic Microenvironment. Vaupel P and Jain RD. (eds) pp. 65-85. Gustav Fisher: Stuttgart
13. Cobbs CS, Brenman JE, Aldape KD, Bredt DS and Israel MA (1995) Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 55: 727-730
14. Cole S, Stratford IJ, Bowler J, Nolan J, Lorimore S, Wright E and Adams GE (1991) Oral (po) dosing with RSU1069 or RB6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice. Int J Radiat Oncol Biol Phys 21: 387-395
15. Cole S, Stratford IJ, Fielden EM, Adams GE, Leopold W, Elliot W, Suto M and Sebolt-Leopold J (1992) Dual function nitroimidazoles less toxic than RSU 1069: selection of candidate drugs for clinical trial (RB 6145 and/or PD 130908). Int J Radiat Oncol Biol Phys 22: 545-548
16. Edwards HS, Bremner JCM and Stratford IJ (1991) Induction of tumour hypoxia by tumour necrosis factor and flavone acetic acid. Int J Radiat Biol 59: 419-432
17. Hill SA, Lonergan SJ, Denekamp J and Chaplin DJ (1994) The effect of vinca alkaloids on tumour blood flow. In Oxygen transport to tissue. Vol. 15, Vauple, P. (ed.), pp. 417-422. Plenum Press: New York
18. Hill SA, Sampson LE and Chaplin DJ (1995) Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 63: 119-123
19. Horsman MR, Chaplin DJ, Hill SA, Arnold S, Collingridge, Radacic M, Wood PJ and Overgaard J (1996) Effect of nitro-1-arginine on blood flow, oxgenation and the activity of hypoxic cell cytotoxins in murine tumours. Br J Cancer 74 (suppl. 17): S168-S171
20. Jenkins TC, Naylor MA, O'Neill P, Threadgill MD, Cole S, Stratford IJ, Adams GE, Fielden EM, Suto MJ and Steir MA (1990) Synthesis and evaluation of 1-(3-(2-haloethylaminolpropyl)-2-nitrimidazoles as pro-drugs of RSU1069 and its analogs, which are radiosensitizers and bioreductively activated cytotoxins. J Med Chem 33: 2603-2610
21. Kruvv JA, Inch WR and McCredie JA (1967) Blood flow and oxygenation of tumours in mice II. Effects of vasodilators. Cancer 20: 60-65
22. Meyer RE, Shan S, DeAngelo J, Dodge RK, Bonaventura J, Ong ET and Dewhirst MW (1995) Nitric oxide synthase inhibition irreversibly decreases perfusion in R3230Ac rat mammary adenocarcinoma. Br J Cancer 71(6): 1169-1174
23. Moncada S, Palmer RMJ and Higgs EA (1991) Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43: 109-142
24. Moulder JE, Jean Dutreix J, Rockwell S and Siemann DW (1988) Applicability of animal tumor data to cancer therapy in humans. Int J Radiat Oncol Biol Phys 14: 913-927
25. Naylor MA, Threadgill MD, Hollis-Showalter HD, Stratford IJ, Stephens MA, Fielden EM and Adams GE (1993) Synthesis of the enantiomers of the bioreductively activated cytotoxin RSU1069 and its prodrug RB6145 and lack of stereoselectivity in their cytotoxicity and radiosensitization in vitro. Drug Design and Discovery 10: 249-255
26. Pluznik DH and Sachs L (1965) The cloning of normal 'mast' cells in tissue culture. J Cell Comp Physiol 66: 319-324
27. Rosbe KW, Prazma J, Petrusz P, Mims W, Ball SS and Weissler MC (1995) Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck. Otolaryngology Head & Neck Surgery 113: 541-549
28. Sheldon PW and Hill SA (1977) Hypoxic cell radiosensitizers and local control by X-ray of a transplanted tumor in mice. Br J Cancer 35: 795-808
29. Stephens TC and Peacock JH (1978) Cell yield and cell survival following chemotherapy of the B16 melanoma. Br J Cancer 38: 591-597
30. Stratford IJ, Adams GE, Godden J, Howells N, Nolan J and Timpson N (1988) Potentiation of the anti-tumor effect of melphalan by the vaso-active drug, hydralazine. Br J Cancer 58: 122-128
31. Stratford IJ, Adams GE, Godden J and Howells N (1989) Induction of tumour hypoxia post-irradiation: a method of increasing the sensitizing efficiency of misonidazole and RSU1069 in vivo. Int J Radiat Biol 55: 411-422
32. Stratford IJ, Adams GE, Bremner JCM, Cole S, Edwards HS, Robertson N and Wood PJ (1994) Manipulation and exploitation of the tumour environment for therapeutic benefit. Int J Radiat Biol 65: 85-94
33. Thompson JE and Rauth AM (1974) An in vivo assay to measure viability of KHT tumor cells not previously exposed to culture condition. Radiat Res 58: 262-276
34. Thomsen LL, Lawton FG, Knowles RG, Beeslev JE, Riveros-Morena V and Moncada S (1994) Nitric ovide synthase activity in human gynecological cancer. Cancer Res 54: 1352-1354
35. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knwles RG and Moncada S (1995) Nitric oxide synthase activity in human breast cancer. Br J Cancer 72: 41-44
36. Tozer GM, Prise VE and Bell KM (1995) The influence of nitric oxide on tumour vascular tone. Acta Oncologica 34: 373-377
37. Twentyman PR, Brown JM, Gray JM, Franko AJ, Scoles MA and Kallman RF (1980) A new mouse tumour model system (RIF-1) for comparison of endpoint studies. J Natl Cancer Inst 64: 545-604
38. Veszelowsky E, Thomsen LL, Zhuang L and Baguley BC (1993) Flavone acetic acid and 5,6 dimethyl xanthenone-4-acetic acid: relationship between plasma nitrate elevation and induction of necrosis. Eur J Cancer 29: 404-408
39. Walton MI and Workman P (1988) Pharmacokinetics and metabolism of the mixed function hypoxic cell sensitizer prototype RSU-1069 in mice. Cancer Chemother Pharmacol 22: 275-280
40. Wood PJ, Stratford IJ, Adams GE, Szabo C and Vane JR (1993) Modification of energy metabolism and radiation response of a murine tumour by changes in nitric oxide availability. Biochem Biophys Res Comm 192: 505-510
41. Wood PJ, Sansom JM, Butler SA, Stratford IJ, Cole SM, Szabo C, Thiemermann C and Adams GE (1994a) Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor NG-nitro L-arginine I. Cancer Res 54: 6458-6463
42. Wood PJ, Sansom J, Stratford IJ, Adams GE, Szabo C, Theimermann C and Vane JR (1994b) Modification of metabolism in transplantable and spontaneous tumors by the nitric oxide synthase inhibitor nitro-L-arginine. Int J Radiat Oncol Biol Phys 29: 443-447